By Digifin Pty Ltd · About this coverage
Key Points
- Group proceeding filed against CSL in the Supreme Court of Victoria
- Covers persons who acquired CSL securities between 11 February 2025 and 11 May 2026
- Allegations include breaches of continuous disclosure obligations
- CSL denies any liability and will defend the proceeding
About CSL (ASX:CSL)
CSL Limited is an ASX-listed biotechnology company headquartered in Melbourne. It collects human plasma and manufactures plasma-derived and recombinant therapies for immunodeficiency, bleeding disorders and other rare and serious conditions, alongside iron deficiency and nephrology medicines and seasonal influenza vaccines.
CSL (ASX:CSL) has disclosed that a group proceeding naming it as defendant has been filed in the Supreme Court of Victoria, and says it will defend the claim.
CSL was notified of the proceeding late in the afternoon of Wednesday 21 October 2026. It is brought on behalf of persons who acquired an interest in certain CSL securities between 11 February 2025 and 11 May 2026 (inclusive). The proceeding includes allegations that CSL breached provisions of the Corporations Act 2001 (Cth), the Australian Securities and Investments Commission Act 2001 (Cth), the Australian Consumer Law and the ASX Listing Rules, including with respect to its continuous disclosure obligations and representations allegedly made about its medium-term performance, expected FY26 revenue and net profit, and/or information about its likely FY26 performance. CSL says it considers it has at all times complied with its disclosure obligations and denies any liability.
The release does not name the applicant, quantify the amount claimed, or say whether CSL expects any financial impact from the proceeding.
Source: CSL Limited (ASX:CSL), 22 October 2026. Summary content supplied by Digifin Pty Ltd.
News summary only, not financial advice. It does not consider your objectives, financial situation or needs.